Business Context and Reporting Period
Company: Acadia Pharmaceuticals Inc. (ACAD)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2024
Business Overview: A biopharmaceutical company focused on central nervous system (CNS) disorders and rare diseases. The company operates two core franchises: neuroscience (anchored by NUPLAZID for Parkinson's disease psychosis) and neuro-rare diseases (anchored by DAYBUE for Rett syndrome). As of December 31, 2024, the company had 654 employees.
Key Financial Metrics
| Metric | 2024 | 2023 |
|---|---|---|
| Net Product Sales | $957.8 million | $726.4 million |
| Cost of Product Sales | $81.8 million | $41.6 million |
| Gross Margin | 91.5% | 94.2% |
| Research & Development Expenses | $303.2 million | $351.6 million |
| Selling, General & Administrative Expenses | $488.4 million | $406.6 million |
| Net Income (Loss) | $226.5 million | ($61.3 million) |
| Cash, Cash Equivalents & Investments | $756.0 million | $438.9 million |
| Accumulated Deficit | ($2.2 billion) | ($2.4 billion) |
Note: The 2024 Net Income includes a one-time gain of $146.5 million from the sale of a Rare Pediatric Disease Priority Review Voucher (PRV).
Material Changes vs. Prior Period
- Revenue Growth: Net product sales increased 31.9% to $957.8 million, driven by a 10.9% increase in NUPLAZID sales ($609.4 million) and a 96.6% increase in DAYBUE sales ($348.4 million).
- Profitability Shift: The company transitioned from a net loss of $61.3 million in 2023 to a net income of $226.5 million in 2024. This reversal was primarily due to the $146.5 million gain on the sale of the PRV and increased operating income from product sales.
- Expense Fluctuations:
- R&D: Decreased by $48.4 million (13.8%) primarily due to the absence of the $100 million upfront payment to Neuren made in 2023 for the expanded trofinetide license.
- SG&A: Increased by $81.8 million (20.1%) due to higher marketing costs for NUPLAZID and DAYBUE and investments in international commercialization.
- Liquidity: Cash and investment securities increased by $317.1 million to $756.0 million, supported by strong operating cash flow of $157.7 million.
Guidance, Outlook, and Risks
Outlook and Pipeline
- DAYBUE Expansion: Marketing authorization granted in Canada (October 2024); Marketing Authorization Application (MAA) submitted to the European Medicines Agency (EMA) in January 2025 with approval expected in Q1 2026. Japan discussions ongoing.
- ACP-101 (PWS): Phase 3 COMPASS PWS study initiated; top-line results expected in H1 2026.
- ACP-204 (ADP): Phase 2 RADIANT study ongoing; Phase 2 study in Lewy Body Dementia with Psychosis (LBDP) planned for Q3 2025.
- ACP-711 (Essential Tremor): Exclusive license acquired from Saniona; Phase 2 study planned for 2026.
Management Commentary
Management expects cash, cash equivalents, and investment securities to be sufficient to fund planned operations through and beyond the next 12 months. The company anticipates cost of product sales as a percentage of net sales will rise to a mid-single digit to high single digit percentage once "zero cost" inventory (manufactured pre-approval) is depleted, expected in 2025.
Risks and Contingencies
- Regulatory Approval: Commercial success outside North America depends on obtaining regulatory approval for DAYBUE in the EU and Japan.
- Patent Litigation: Ongoing patent infringement lawsuits regarding NUPLAZID (Pimavanserin) against MSN and Aurobindo. A final judgment was entered in favor of Acadia in the Pimavanserin I Case (MSN appeal pending), and a bench trial concluded in the Pimavanserin II Case (decision pending).
- Securities Litigation: Putative securities class action and derivative suits regarding prior disclosures related to pimavanserin for dementia-related psychosis remain pending.
- Reimbursement: Risks related to third-party payor coverage, pricing pressures, and the implementation of the Inflation Reduction Act (IRA) rebate requirements.
Investor Verification Checklist
- PRV Sale Proceeds: Verify the net proceeds of $146.5 million from the PRV sale and the subsequent $48.8 million payment to Neuren (one-third of net proceeds) made in February 2025.
- DAYBUE Cost Structure: Monitor the transition from "zero cost" inventory to full-cost inventory in 2025 and its impact on gross margins.
- Neuren Milestone Payments: Confirm the $50 million milestone payment due to Neuren in 2025 triggered by exceeding $250 million in North American net sales for trofinetide in 2024.
- Patent Litigation Status: Track the outcome of the MSN appeal in the Pimavanserin I Case and the final court decision in the Pimavanserin II Case.
- International Expansion: Monitor the timeline for EMA approval of DAYBUE (expected Q1 2026) and commercial launch in Canada (expected Q3 2025).